Artiva Biotherapeutics Inc. ARTV

$11.77 -0.23 (-1.92%)

Valuation

Market cap
—
Revenue TTM
$33,492,000
Net income TTM
$-27,696,000
PE ratio
—
Forward PE
—
Profit margin
—
Debt to equity
—

Trading

Volume
342,500
Avg volume
—
Day's range
$11.71 – $12.26
Shares out
—
Stochastic %K
—
Beta
—
Analysts
Strong Buy
Price target
—

Price

Company profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis,...

Show more

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 267 4467
Website
https://www.artivabio.com
Address
5505 Morehouse Drive, Suite 100, San Diego, United States

Latest news

Stocktwits

Rocketman808 Oct 9, 11:26 AM
$ARTV too good to ignore any longer.
0 replies
Merlintrader Oct 6, 2:56 PM
Latest company news, October 2: Artiva announced multiple AlloNK data presentations at the ACR meeting and a November 9 clinical webcast. Artiva Biotherapeutics ($ARTV): AlloNK Sjögren Follow-up Reported October 1 Explore the company, catalysts and risks in our research hub. https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/
0 replies
focafoca99 Oct 2, 1:25 PM
$ARTV introduces multiple AlloNK data presentations at ACR Convergence 2026, showcasing updated RA, Sjögren and systemic sclerosis results.
0 replies
YouVSYou Sep 30, 12:52 AM
$QURE Beautiful dip today 30%++ $BKYI 53% $CTNT 15% More in the chat daily 24/7 $ARTV Top Watch With $SENS
0 replies
Papermoon347 Sep 29, 1:32 PM
$ARTV whom ever buys this stock is smart ,whom ever sells needs money or a complete idiot .
0 replies
YouVSYou Sep 29, 1:53 AM
$ARTV interest $OOMA $ALZN $OCUL $KYTX Eyes on it
0 replies
dougdchef Sep 28, 6:51 PM
$ARTV pulling a G.Castanza
0 replies
YouVSYou Sep 28, 1:15 PM
$ARTV $OCUL Ww this week $SCYX @BOUDIN420 aleeted the team Friday before the Chase $NVDA but back into res 230.77/228.85 $SOAR .34/.45
0 replies